Alexion Pharmaceuticals, Inc. v. Samsung Bioepis Co. Ltd.
1:24-cv-00005
Overview
Parties
Defendant
Samsung Bioepis Co. Ltd. Operating Company
Represented By
7 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Plaintiff
Alexion Pharmaceuticals, Inc. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
405 N. King Street, Wilmington, DE 19801
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Counter Defendant
Alexion Pharma International Operations Ltd. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
405 N. King Street, Wilmington, DE 19801
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Amgen, Inc. v. Alexion Pharmaceuticals, Inc.
Patents Involved
There are 6 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9732149
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
Filed: 2016-10-03
Issued: 2017-08-15
|
Active (9.9 yrs remaining)
Expires: 2036-10-03
|
|
|
US9718880
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
Filed: 2016-05-06
Issued: 2017-08-01
|
Active (9.5 yrs remaining)
Expires: 2036-05-06
|
|
|
US9725504
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
Filed: 2016-09-09
Issued: 2017-08-08
|
Active (9.8 yrs remaining)
Expires: 2036-09-09
|
|
|
US10590189
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
Filed: 2017-07-05
Issued: 2020-03-17
|
Active (0.8 yrs remaining)
Expires: 2027-09-08
|
|
|
US10703809
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
Filed: 2020-02-28
Issued: 2020-07-07
|
Active (13.3 yrs remaining)
Expires: 2040-02-28
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
27
Dispositive
21
Granted
0
Denied
2
Pending / Review
23
Motions by Category
Key Dispositive Motions & Rulings